Vernalis
We develop and apply fragment and structure -based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti -infectives and inflammation.
Our established group of experienced scientists is based at our fully -equipped research laboratories in Cambridge, UK. We integrate fragment -based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.
We have the experience and capabilities for progressing projects from target identification through to clinical candidate. We have generated lead compounds on enzymes, protein -protein interactions and GPCRs, leading to an average of one pre -clinical candidate per year, with disclosed programs for inhibitors of Chk1, Hsp90, Bcl -2, Mcl -1, FAAH and A2A.Previous and on -going collaborations include Novartis, Genentech, Servier, Lundbeck and Daiichi Sankyo.
Ben Davis
Research Fellow and Director of Business Development
